Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.
Also called NCT01103414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 356 participants
- Sponsor
- Metabolic Solutions Development Company
- Registry
-
NCT01103414
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01103414. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-03-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Mitoglitazone
- Intervention (Drug)
- Mitoglitazone
- Intervention (Drug)
- Mitoglitazone
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Metabolic Solutions Development Company
Record details
- Record id
cardio:ct-nct01103414- Content hash
20c36f578a2c33372af853bc7def6b30facd5b05a97c4a6bcd5985c1d89cd07c